A Robot That Takes Blood: The Potential Game-Changer in AI Health for 2026
A Dutch robot has achieved a significant milestone in medicine by performing a seemingly mundane task with remarkable efficiency.
The FDA Authorization
On August 19, 2026, the U.S. Food and Drug Administration (FDA) authorized Aletta, a robotic device developed by Vitestro, through the De Novo pathway. This landmark event makes Aletta the first standalone robotic device cleared to draw blood without human intervention.
The Challenge and Solution
For years, the healthcare industry has anticipated groundbreaking advancements from artificial intelligence, such as drug discovery and improved scanning capabilities. However, Vitestro took a different approach by focusing on a basic yet crucial procedure: blood draws (read more here).
The company conducted a clinical trial in Dutch hospitals, demonstrating that Aletta could successfully draw blood in just one minute and 49 seconds, on average, compared to a human phlebotomist's typical time of around five minutes.
Addressing a Growing Shortage
Blood draws are one of the most common medical procedures in the U.S., but the industry faces a growing shortage of trained phlebotomists. This innovation aims to alleviate the burden on healthcare professionals and reduce patient wait times.
Key Achievements
- 95% first-stick success rate compared to a manual benchmark of 93-97%.
- 0.6% haemolysis rate, well below the best-practice ceiling of 2%.
- Mild adverse events were recorded in only 1.3% of participants, with no serious or moderate events.
Important Considerations
The FDA's special controls emphasize that manufacturers must prove performance comparable to or better than trained human phlebotomists across diverse patient populations, including those with varying health statuses, difficult vein access, and different skin tones.
This authorization highlights the potential of robotic devices to enhance healthcare accessibility and efficiency, especially in procedures that are often overlooked but essential.